Daina Graybosch, an analyst from Leerink Partners, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price target was raised to $115.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Daina Graybosch’s rating is based on BioNTech’s strategic partnership with BMY, which significantly enhances BioNTech’s competitive position in the oncology sector. The collaboration focuses on the development of BNT327, a PD-L1 x VEGF-A bispecific, which is expected to provide added value when combined with BMY’s established and novel assets. The deal is seen as a positive move, as it leverages BMY’s extensive expertise in clinical trial development, addressing BioNTech’s previous challenges in late-stage oncology development.
Furthermore, the partnership includes a substantial financial agreement, with BMY committing to significant upfront and milestone payments to BioNTech. This financial backing not only supports the development of BNT327 but also reflects confidence in BioNTech’s management team, which has demonstrated strong business acumen and leadership. The deal is expected to spread risk, preserve BioNTech’s balance sheet, and facilitate the growth of internal capabilities, reinforcing the company’s potential for future success.
In another report released on June 3, Canaccord Genuity also maintained a Buy rating on the stock with a $171.00 price target.
BNTX’s price has also changed slightly for the past six months – from $117.200 to $113.100, which is a -3.50% drop .